RDA P17- ‘COVID-19 Vaccine Data & Public Health Decision-making’

You are here

27 Jan 2021
Group(s) submitting the application: 
Meeting objectives: 

Meeting Objectives

The principal objective of this session is to examine the role and impact of data sharing on COVID-19 vaccine data sharing on public health decision-making. The rollout of the first COVID-19 vaccines through Emergency Medical Authorization and similar procedures, including the first introduction of mRNA vaccines, has highlighted the need for the sharing of reliable pre-clinical, clinical, and pharmacovigilance data for public health decision making. The first generation COVID-19 vaccines are being complemented by the additional development of new vaccines. Governments, with the support of vaccine experts and public health officials, face difficult decisions regarding vaccine allocation, posology, and pharmacovigilance.

The specific objectives include the following:

  1. An examination of COVID-19 data sharing practices by vaccine manufacturers;
  2. An examination of COVID-19 vaccine data sharing practices by government regulatory authories;
  3. WHO and other international guidances on COVID-19 vaccine data sharing;
  4. A review of COVID-19 vaccine data sharing practices and their potential impact on posology decision-making by public health authorities; and
  5. Steps to improve COVID-19 vaccine data sharing practices between HICs and LMICs to better improve COVID-19 vaccine knowledge and vaccine implementation by public health experts
Meeting agenda: 

Collaborative meeting notes (main session): https://docs.google.com/document/d/1NZmtKAPOScNjID5ZrmYLaZ-D3Fle2NbOhH41qYsdkiM/edit?usp=sharing

Collaborative meeting notes (repeat session)https://docs.google.com/document/d/1gAWnGoTqZqd-W1MVhxV7FiyVxuu7rzUchZHdLNtP_QY/edit?usp=sharing

 

Meeting agenda *

Part 1: Presentations (45-50­­­ min)

An examination of current frameworks for COVID-19 vaccine data sharing relevant COVID-19 vaccine public health decision-making

Speakers to be confirmed; 1 from a manufacturer of a COVID-19 vaccine; 1 from a regulatory authority; 1 from an ethics committee, 1 from government public health advisor on vaccines; 1 from a patient (vaccinee). Maximum 5 speakers (speakers to be confirmed)

Part 2: Interactive discussion: 40-45 min (Moderators: Two moderators and panellists to be confirmed)

  1. The impact of COVD-19 vaccine data sharing on posology decision-making
  2. The impact of COVID-19 vaccine data sharing on pharmacovigilance
  3. Steps to improved COVID-19 vaccine data sharing to improve public health outcomes

Conclusion

Actions points for contributing to a potentially new chapter on Vaccinations to the existing RDA COVID-19 Recommendations and Guidelines.

Target Audience: 

Target Audience *

Public health experts; Vaccine researchers; Regulatory authorities; Vaccine data service providers; ethics committee members; staff of health authorities; data protection authorities; those managing vaccine data repositories. policymakers, research funders, institutions, publishers

Group chair serving as contact person: 
Brief introduction describing the activities and scope of the group: 

 

Brief introduction describing the activities and scope of the group *

 The RDA-COVID-19 legal-ethical working group is an interdisciplinary group set up first as a sub-group of the 2020 RDA COVID-19 working group. As described above it addresses in terms of reference documents, guidelines and recommendations the legal and ethical aspects in sharing data related to COVID-19, with the objective of preparing paths in case of future pandemics. Beyond contributing to the document produced by the whole WG COVID-19 with all its sub-groups, it sustains a follow-up work in order to update the issues to address and draw conclusions from confronting to the reality of the evolving pandemic and the documents endorsed in June 2020.  (See above  description of the work done and current work, in objectives) The working group will include a subsection on potentially the A new chapter on Vaccinations to eventually be included in the existing RDA COVID-19 Recommendations and Guidelines. (A proposal is in development.)

 

Short Group Status: 

Short Group Status

Established working group since April 2020; Outputs so far: recommendations with other COVID-19 WG; publication;

Estimate of the required room capacity (Hybrid plenary): 
50-60 (Hybrid Plenary)
Type of Meeting: 
Working meeting
Meeting presenters: 
To be confirmed